Do you have a cut-off for bilirubin for treatment of patients with poorly differentiated NSCLC with good PS and liver dysfunction due to mets?   

The management of patients with extensive liver mets resulting in elevated bilirubin depends upon the clinical scenario.  The question posed indicates this patient has a good performance status and a lung cancer histology of "poorly differentiated NSCLC".  The factors that I would consider...